other material
confidence high
sentiment positive
materiality 0.65
Phio reports 2 complete responses in PH-762 Phase 1b second cohort for cutaneous squamous cell carcinoma
Phio Pharmaceuticals Corp.
- 2 of 4 patients in 2nd cohort achieved 100% tumor clearance (complete response).
- 1 patient had 90% tumor clearance (partial response); 1 had stable disease.
- No dose-limiting toxicities or clinically relevant adverse events reported.
- INTASYL siRNA gene silencing therapy PH-762 is being evaluated in NCT 06014086.